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Abstract
We analyze whether the possibility for physicians to dispense drugs increases health care
expenditures due to the incentives created by the markup on drugs sold. Using compre-
hensive physician-level data from Switzerland, we exploit the fact that there is regional
variation in the dispensing regime to estimate policy effects. The empirical strategy
consists of doubly-robust estimation which combines inverse-probability weighting with
regression. Our main finding suggests that if dispensing is permitted, physicians produce
significantly higher drug costs in the order of 30% per patient.
Keywords: health care costs; drug expenditures; physician dispensing; supply-induced
demand; treatment effects.
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1 Introduction
As many developed countries are faced with continuously rising health care costs,
knowledge on inefficiencies in health care provision is very important in shaping
reforms. One potential source of such inefficiencies are the conflicting incentives for
physicians who act both as entrepreneur and as the patient’s agent. Therefore, many
countries maintain policies that attempt to disentangle the physician’s double role.
One important such policy, and the central issue of this paper, is the regulation of
drug dispensing by physicians. While some Western countries including the United
States, the United Kingdom, Japan and Switzerland (partly) allow physicians to
dispense drugs1, several OECD countries fully ban physician dispensing. This is due
to concerns that physicians are incentivized to induce demand or substitute towards
more expensive drugs if they earn a profit margin on drug sales. However, the
literature on the effects of physician dispensing on drug or health care expenditures
is very small and empirical evidence is scarce (an overview is provided by Lim et
al., 2009). Therefore, the objective of this paper is to examine empirically whether
the possibility for physicians to dispense affects prescription drug expenditure. To
our knowledge, we are the first to estimate the causal effect of physician dispensing
on health care expenditures.
Examining the Swiss case is particularly interesting for at least three reasons.
First, both dispensing rules (banned/allowed) co-exist in Switzerland because the
rule is determined on the cantonal (i.e. state) level. This regional variation in
the dispensing regime allows for the identification and estimation of policy effects.
Second, drug prices are set by federal regulators, i.e. prices are the same throughout
the country such that the comparison of drug costs is not confounded by regional
price differentials. Moreover, fully regulated prices imply that the only channel
through which physicians can affect drug expenditure is through quantities or the
composition of drugs prescribed. Third, the coverage of mandatory health insurance
is the same for the whole permanent resident population of Switzerland such that
drug expenditures are not likely to be affected by insurance choice.2
For our empirical analysis, we study a comprehensive dataset on the prescribing
costs of specialized physicians in Switzerland. Applying doubly-robust regression
methods (see Imbens and Wooldridge, 2009), our benchmark estimates suggest that
1In the United States for example, physicians are allowed to dispense drugs in most states with
the exception of Massachusetts, Montana, New York, Texas, and Utah (see Rodwin and Okamoto,
2000).
2Further details on the Swiss health care system can be found in Health Care Systems in
Transition report on Switzerland (European Observatory on Health Care Systems, 2000) and The
OECD Review of Health Systems: Switzerland (OECD/World Health Organization, 2011).
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physician dispensing increases drug expenditures per patient by roughly 30% (CHF
75). In addition, total non-drug expenditures increase as well by about 20% (CHF
100) per patient. These results suggest that, in the context of policy-induced health
care expenditures, drugs costs and non-drug costs are complementary. This lends
support to the notion that over-prescribing raises consultation costs through an
increase in the total time of treatment. On the whole, our findings suggest that the
dispensing policy clearly affects the prescribing behavior of physicians in ways that
affect health care expenditures.
The remainder of this paper is organized as follows. Section 2 reviews the relevant
literature and Section 3 provides information on the institutional background in
Switzerland. In Section 4, we discuss identification and estimation of treatment
effects in our framework. Section 5 contains the empirical analysis: we explain the
construction of the dataset, present descriptive statistics, perform robustness checks
with regard to the common support, and discuss the main results (in Section 5.4).
Section 6 contains some concluding remarks.
2 Related Literature
In spite of a large literature on physician behavior and demand inducement (see, e.g,
Labelle et al., 1994; McGuire, 2000), comparatively little evidence exists regarding
their dispensing practice. The most thoroughly analyzed aspect of physician behav-
ior related to drugs is their prescription practice in terms of generic and trade-name
medicine (see, e.g., Hellerstein, 1998; Coscelli, 2000; Lundin, 2000). However, the
results in this literature are mostly based on data from countries without physi-
cian dispensing. Three exceptions are Liu et al. (2009), Rischatsch et al. (2009),
and Iizuka (2007, 2012), where the authors find for Taiwan, Switzerland and Japan,
respectively, that markup differentials between generic and trade-name drugs af-
fect physicians’ dispensing behavior. In addition, Park et al. (2005) find that the
introduction of a dispensing ban in South Korea led to a reduction in antibiotic pre-
scriptions. A similar result is found by Filippini et al. (2013) who compare antibiotic
prescriptions between dispensing and non-dispensing doctors in Switzerland. While
these results consistently suggest that physicians respond to financial incentives, no
conclusions can be drawn as to how physician dispensing affects aggregate health
care expenditures.
A much smaller strand of the literature focuses on the impact of physician dis-
pensing on health care expenditures. Chou et al. (2003) analyze the impact of the
dispensing ban that was implemented sequentially in Taiwan and find a substan-
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tial decrease in the drug expenditures per visit. However, the effect on aggregate
health care expenditures remains unclear due to a simultaneous increase in con-
sultation fees. Baines et al. (1996) and Dummermuth (1993) find for Lincolnshire
(United Kingdom) and two Swiss cantons, respectively, that dispensing physicians
trigger more drug expenditures per patient than their non-dispensing counterparts.
However, these studies essentially compare differences in means and do not con-
trol for compositional differences in the patient populations of dispensing and non-
dispensing physicians. In a more recent study for Switzerland, Beck et al. (2004)
estimate the effect of the cantonal (i.e. state) dispensing policy controlling for other
determinants of drug demand. Using canton-level data, the authors find that physi-
cian dispensing considerably increases drug expenditures. However, comparisons
only on the canton level are problematic due to small sample size and unobserved
canton-specific heterogeneity.
While some of the mentioned studies credibly suggest that financial incentives
affect physicians’ prescription choice (e.g. generic vs. brand-name), the question as
to how dispensing affects health care expenditures has largely remained unanswered
due to inconclusive empirical evidence. Our main contribution to the literature is
therefore to estimate causal effects of the dispensing policy rule (allowed vs. banned)
on drug as well as non-drug expenditure. Such estimates provide direct information
on the health care costs of physician dispensing and are therefore of high relevance
for health care policy. In addition, they add to the literature on physician behavior
in the presence of monetary incentives.
3 Drug Dispensing and Pricing in Switzerland
The Swiss pharmaceutical market is highly regulated on the federal level with respect
to drug approval, pricing and dispensing. In principle, all licensed pharmacists are
allowed to sell prescription drugs, but they cannot issue prescriptions. In contrast,
all medical doctors can issue prescriptions by federal regulation, but cantons either
prohibit or (partially) permit doctors to dispense drugs. In the time period consid-
ered in this paper (2008-2010), five cantons prohibit physician dispensing completely
and four cantons have policies that result in a de facto ban. Thirteen cantons allow
physician dispensing without any restrictions and four cantons partially allow it in
rural areas or communities with low pharmacy densities (see Appendix A.1 for fur-
ther details). These canton-specific regulations did not change during the period of
interest and had been in place since at least the 1980s. Thus, the observed variation
in the dispensing regime is rooted in historical differences between cantonal health
3
care policies.
It is important to note that, while German-speaking cantons have some vari-
ation in the dispensing rule, all cantons in the French and Italian speaking parts
of Switzerland ban physician dispensing. This means that we cannot control for
language region in the estimation procedures. As a consequence, we restrict our
analysis to the German-speaking area given the evidence of culture-specific differ-
ences in health care consumption and expenditures (see, e.g., Vatter and Ruefli,
2003; Crivelli et al., 2006; Reich et al., 2012).
An important fact about the Swiss drug market is that ex-factory prices as well
as retail prices of all drugs covered by mandatory health insurance are determined by
federal regulations. The price of pharmaceuticals charged by a dispensing physician
corresponds to the retail price plus 2.5% VAT, such that his gross profit margin
corresponds to the difference between the retail price and the ex-factory price. For
example, for drug with an ex-factory price of CHF 100, the physician charges the
patient CHF 128, thus earning a markup of CHF 28 per package (see Appendix A.2).
Another crucial feature is that the absolute markup is increasing in the ex-factory
price.
In addition, pharmacies charge higher prices than physicians due to two ad-
ditional lump-sum fees. Given this price setting regime, the pharmacist earns an
excess markup compared to the physician (see Appendix A.2 for further details). To
appropriately compare the costs between dispensing and non-dispensing physicians,
our analysis focuses on real expenditures, which means that all drug costs are based
on retail prices excluding the pharmacists’ excess markup.3 The reason is that the
effect of dispensing on real costs is more informative about physician behavior in
the face of monetary incentives.
4 Methodology
4.1 Identification of Treatment Effects
To estimate the effect of the dispensing policy on drug expenditures, we use the
potential-outcomes framework which has become standard in causal analysis (Rubin,
1974). Consider a large population of physicians indexed by i = 1, 2, ...N . Let Di
be an indicator variable with Di = 1 if physician i is allowed to dispense drugs
directly and Di = 0 if physician i is forbidden to do so. We regard the permission
3The term “real” refers to constant prices in the cross-section dimension. However, we also
adjust costs across different years for inflation, such that “real” also applies to the time-series
dimension. We explain how we adjust for pharmacy prices in the Online-Appendix C.
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to dispense as the “treatment” and thus refer to the two groups as treatment group
and control group, respectively. Denote Y1i and Y0i the potential expenditures that
physician i triggers if he is either dispensing or non-dispensing, respectively. Since
we only observe Y1i if Di = 1 and Y0i if Di = 0, the realized outcome may be written
as Yi = DiY1i + (1 − Di)Y0i.
The quantity of interest is the average causal effect of dispensing on drug expen-
ditures in the physician population
τ = E[Y1i − Y0i], (1)
commonly known as the population average treatment effect (ATE). This effect is
informative about the average costs associated with the policy that admits dispensa-
tion for all physicians relative to the policy that bans dispensation for all physicians.
Moreover, it is instructive to consider the average effect for the group of dispensing
physicians:
ρ = E[Y1i − Y0i|Di = 1]. (2)
This quantity is referred to as the population average treatment effect on the treated
(ATT). This effect is informative about the cost consequences of the current policy
relative to the policy that bans dispensation for all physicians. Obtaining consistent
estimates of the objects in (1) and (2) is the main goal of the empirical analysis in
this paper.
The main issue with treatment effects is to ensure identification. Let Xi denote
a vector of covariates capturing personal characteristics of physician i and various
supply and demand conditions at physician i’s location (e.g. physician density,
health status and insurance coverage, demographic and socio-economic factors). A
prominent result from the causal inference literature states that (1) and (2) are
identified under the following assumptions (cf. Imbens, 2004):
(Yi0, Yi1) ⊥ Di|Xi = x (3)
0 < p(x) < 1 ∀x ∈ X , (4)
where p(x) ≡ P (Di = 1|Xi = x) is the propensity score and X ⊂ Rk is the support of
Xi. The conditional independence assumption in (3) states that once we control for
the characteristics in Xi, treatment status is as good as randomly assigned and thus
independent of potential outcomes. Put differently, comparing observations with the
same covariate values, any systematic difference in outcomes across treatment and
control group is due to the dispensing policy Di. Although (3) is intestable, we argue
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that our setting renders (3) likely to be satisfied. First, our empirical framework has
the advantage that the dispensing policy is determined by institutions on the regional
level, such that the possibility for physicians to influence their treatment group
assignment is strongly restricted. At the same time, other institutional features
such as drug prices and health insurance regulations are the same throughout the
country. Second, we can control for several personal characteristics of physicians.
This eliminates any potential bias that arises if these characteristics affect both
practice style and treatment assignment. Finally, as shown in the empirical analysis,
we can effectively control for health care market conditions in the practice location.
This ascertains that only dispensing and non-dispensing doctors are compared that
face similar supply and demand conditions in the local health care market.
The common support assumption in (4) implies that, for all possible values of
Xi, we can match dispensing doctors with non-dispensing doctors. This assumption
is testable and we will show in the empirical analysis how the sample is restricted
to the common support if (4) is violated for a subset of the observations.
As shown for example in Imbens (2004), assumptions (3) and (4) imply that the
ATT and the ATE are identified as follows:
ρ = E[Δ(x)|Di = 1] (5)
τ = E[Δ(x)] (6)
where Δ(x) ≡ E[Yi|Xi = x,Di = 1]−E[Yi|Xi = x,Di = 0]. Given this identification
result, the remaining task is to estimate the conditional expectation functions with
appropriate econometric techniques.
4.2 Estimation
There are several empirical strategies available for estimating treatment effects under
assumptions (3) and (4). We choose to focus on a method that combines regression
with propensity score weighting, also referred to as ”doubly robust” regression. The
doubly robustness property is particularly appealing because, as discussed below,
the estimator is consistent under two separate sets of assumptions (Robins et al.,
2007). Imbens and Wooldridge (2009) recommend this approach explicitly because
it is found to perform especially well if covariate distributions differ substantially
across groups.4
4Note that we do not consider matching methods because we have clusters of repeated ob-
servations. Unfortunately, for matching estimators, the bootstrap is generally not valid (Abadie
and Imbens, 2008) and analytical variances of matching estimators are difficult to compute for
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Estimation proceeds in several steps. First, the propensity score is estimated
with a binary probability model. The predicted values, p̂(Xi), are then used to
compute inverse-probability weights (IPW): λ̂ρ(Xi) =
(
Di +
p̂(Xi)
1−p̂(Xi)
(1 − Di)
)
for
the ATT and λ̂τ (Xi) =
(
Di
p̂(Xi)
− 1−Di
1−p̂(Xi)
)
for the ATE. For the second step, define
the parametric regression models for the treatment group and the control group by
m(Xi, β
1) and m(Xi, β
0), respectively. The doubly robust regression estimator β̂d,e
is obtained by solving the following IPW-augmented moment conditions:
Nd∑
i:Di=d
λ̂e(Xi)[Yi − m(Xi, β̂
d,e)]Xi = 0, for di = {0, 1}, e = {ρ, τ} (7)
Finally, the estimated coefficients are used to estimate the ATT and the ATE,
respectively, as follows:
ρ̂ =
1
N1
N1∑
i:Di=1
m(Xi, β̂
1,ρ) − m(Xi, β̂
0,ρ) (8)
τ̂ =
1
N
N∑
i=1
m(Xi, β̂
1,τ ) − m(Xi, β̂
0,τ ) (9)
Using the appropriate propensity-score weights λ̂e(Xi) in the regressions ensures that
treatment effects are consistently estimated under two separate sets of assumptions.
That is, consistency is achieved if either the outcome model is correctly specified
(in which case plim(β̂d,e) = βd), or the propensity score model is correctly specified
(in which case plim(λ̂e(Xi)) = λ
e(Xi)), or both. See for example Robins et al.
(2007) or Wooldridge (2007) for the formal derivation and a detailed discussion of
the doubly robustness result. The main advantage of this type of estimator is that it
guards against misspecification more effectively than traditional methods based on
the propensity score alone or on regression alone. In practice, the outcome model is
normally specified as a linear model such that (7) becomes a weighted least squares
(WLS) estimator. If the outcome model is assumed to be exponential, (7) is the
weighted Poisson quasi-maximum-likelihood estimator (WPQML), see Wooldridge
(2007).5 We will consider both of these specifications in our analysis. Finally,
inference is based on the bootstrap, which takes into account the fact that the
the case of clustered data. In addition to the cluster problem, matching on covariates has the
disadvantage that the asymptotic bias increases in the number of continuous covariates (Imbens,
2004). Matching on the propensity score has the drawback that analytical standard errors do not
exist for the case where the propensity score is estimated.
5This estimator is equivalent to the generalized linear model (GLM) with log-link and Poisson
family augmented with the appropriate weights.
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propensity score in the first step is estimated.
5 Empirical Analysis
The empirical analysis is structured in the following manner. We first describe the
construction of the dataset from the various sources we draw on. Second, we briefly
present descriptive statistics on outcomes and covariates. Third, as a preliminary
robustness check, we determine the common support of the covariate distributions.
Finally, we estimate and discuss the effect of the dispensing policy on health care
expenditure.
5.1 Data Sources and Variables
We have access to physician-level data for the period 2008-2010 provided by the
operator of the nationwide database of Swiss health insurers (Sasis AG). We have
expenditure data on medical specialists delivering outpatient care in private prac-
tices. The dataset basically aggregates the mandatory health insurance claims of
nearly all Swiss health insurance companies.6 The included insurance companies
cover about 90% of the permanent resident population of Switzerland. Although
we do not have individual prescription items as the unit of observation, we estimate
that the data aggregates about 30 million prescriptions annually.7 We consider this
comprehensiveness an important advantage of our data because problems resulting
from adverse selection into individual insurance firms are minimized. Two points
about the data on prescription drugs should be added. First, as is mostly the case
with insurance claims data, out-of-pocket expenditure that patients do not report
to their insurer is not included. This is most likely for patients who only incur small
amounts of health care costs in a given year and are therefore unlikely to exceed
the deductible.8 Second, although the vast majority of drugs covered by mandatory
health insurance require prescriptions, there are some exceptions; roughly 8% are
over-the-counter (OTC) products.9
In the ensuing discussion on the construction of the dataset, the reader is referred
to Table A.3 in Appendix B for a detailed exposition of all variables. For each
6Three out of 61 insurance companies are not included; these are Assura, EGK and SLKK.
7This estimate is based on detailed insurance claims data from one major health insurer with
more than half a million customers. The estimate is based on the assumption that the average
number of prescriptions per person is the same for the remaining population.
8Based on national accounting data on the consumption of pharmaceuticals, we estimate that
our data contains at least 84% of the relevant drug expenditures.
9These include for example painkillers with low dosage or certain herbal products.
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physician, the data contains two separate components of total annual prescribing
costs triggered. First, we observe direct costs (dispensing costs) which arise when a
doctor directly sells drugs to his patients. Second, we observe indirect costs which
arise when a doctor issues prescriptions that are filled in pharmacies. In other
words, the cost for every prescription drug sold in pharmacies can be attributed
to the physician who originally issued the prescription. This feature of the data
is of paramount importance; without it, we would not be able to appropriately
compare expenditures between dispensing and non-dispensing physicians. Besides
drug expenditures, we also observe non-drug medical costs, the number of patients,
the patients’ average age, and the distribution of office visits across age groups
(5-year intervals) and gender.
A further advantage of the data is that every physician can be identified through
his global identifier number (GLN). The GLN can be used to match the expenditure
data to individual characteristics of physicians taken from the register of medical
professionals (MedReg), which is publicly accessible on the internet.10 Variables
include gender, nationality, age and experience. The MedReg database also includes
information on the treatment indicator, Di, i.e. the dispensing permission (cf. Table
A.3 in Appendix B).
Since the dispensing policy varies by region, we want to account for the fact
that physicians face different demand and supply conditions depending on the local
health care market in which they operate. To do this, we exploit the fact that, for
each physician, we observe the distribution of office visits across patients’ place of
residence (municipality). Since we have this detailed knowledge on a physician’s
catchment area, we can effectively control for location-specific determinants of the
health care market. On the supply side, we take into account the local physician
density. On the demand side, we control for the health status and insurance choice
of the local population and for demographic and socio-economic characteristics that
are relevant for consumption of prescription drugs. The latter include, for example,
the degree of urbanization, average income, unemployment, immigration and edu-
cation level. For each physician, we average all these variables across municipalities
using the number of visits from these municipalities as a weight. Since a physi-
cian may draw patients from a much larger area than from just “his” municipality,
the weighted averages effectively capture the characteristics of the location-specific
health care market that are relevant for a particular physician.
In the empirical analysis, we consider medical specialists but exclude psychia-
trists because the nature of their health care provision, the forms of treatment, and
10see http://www.bag.admin.ch/themen/berufe/00411/
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the role of medication are quite different compared to other physicians. In terms
of further sample selection, we decide to drop physicians with less than 10 patients
per year (5% of sample).11 Finally, after combining the datasets and applying the
selection criteria outlined above, we are left a vast majority (roughly 90%) of all
specialized physicians running independent practices in German-speaking Switzer-
land.
5.2 Descriptive Statistics
Tables 1 presents descriptive statistics for our dataset. Expenditure variables are
annual measures expressed in constant 2010 Swiss francs (CHF). As explained pre-
viously, we focus on real expenditures (in the cross-section sense), i.e. all costs are
expressed in retail prices, to facilitate comparability.
In the top panel of Table 1 we see that dispensing doctors have a slightly higher
drug-intensity of treatment than non-dispensing doctors given the larger cost share
of drugs. Furthermore, total annual drug costs are higher by about 50%. One
important issue with total cost measures is that, taken at face value, they are hard to
compare because systematic differences in the composition of the two groups remain
unaccounted for. We see for example that dispensing physicians have larger practice
size, i.e. more patients on average. For these reasons, it makes sense to consider
expenditures per patient.12 Table 1 reveals that dispensing physicians also have
higher drug expenditures per patient compared to their non-dispensing counterparts.
Finally, it is important to note that the shares of dispensing costs in total drug
costs are neither zero nor one. This reflects the fact that non-dispensing physicians
are normally allowed to dispense limited amounts of drugs in case of emergencies.
Conversely, dispensing physicians may have a limited range of pharmaceuticals in
stock such that patients must collect unavailable products at pharmacies.
Turning to the covariates, we see that in areas with dispensing, physicians are
more often male, foreign and somewhat younger. In contrast, the average age and
gender structure in the patient pool appears quite similar across groups. The most
striking differences across groups can be found in the bottom half of Table 1. For
example, regions where dispensing is allowed have considerably smaller physician
11Many of these doctors only report a single patient. According to Sasis AG, these are likely
to be physicians who have retired or quit working for other reasons, but who are still allowed to
prescribe drugs to themselves and/or family member and then file these insurance claims to their
health insurer.
12We do not consider costs per visit because the number of visits in a calendar is directly
affected by the physician’s behavior with regard to the inducement of follow-up visits. In contrast,
the number of patients should not be affected by this.
10
Table 1: Descriptive Statistics (2008-2010)
non-dispensing dispensing
Di = 0 Di = 1
mean st.dev. mean st.dev.
real annual expenditure per physician
cost share of drugs 0.203 0.171 0.213 0.169
drug costs 97974.228 188175.201 150256.099 313663.858
drug costs per patient 243.156 461.466 274.059 704.880
non-drug costs 259054.027 265050.604 376394.745 365633.773
non-drug costs per patient 919.262 868.270 620.105 756.306
share of dispensed drugs 0.120 0.154 0.865 0.194
physician characteristics
female 0.311 0.243
German nationality 0.090 0.126
other foreign nationality 0.017 0.018
age 52.910 8.800 51.052 8.211
work experience 17.339 8.915 16.378 8.005
patient pool variables
# patients 596.860 725.702 942.422 891.956
# visits 1699.686 1657.619 2319.689 1893.149
# visits per patient 5.670 5.008 3.550 2.988
patients’ average age 48.982 11.083 50.244 9.102
cases aged > 80y 0.052 0.071 0.060 0.062
cases aged 66 − 80y 0.176 0.150 0.205 0.138
cases aged < 25y 0.128 0.186 0.119 0.128
cases of males 0.362 0.202 0.361 0.203
characteristics of the local health care market
physician density 3.793 1.305 3.031 1.299
share with very good subj. health 0.206 0.028 0.219 0.035
share with good subj. health 0.674 0.027 0.671 0.036
share with very good obj. health 0.313 0.028 0.325 0.039
share with good obj. health 0.351 0.025 0.354 0.035
share with chronic health problems 0.503 0.035 0.490 0.046
share with high health risk 0.273 0.027 0.253 0.036
share of immigrants 0.217 0.056 0.206 0.045
fraction of urban area 0.354 0.153 0.271 0.107
net income per capita in 1000 80.457 10.824 81.905 15.918
unemployment rate 2.767 0.517 2.506 0.520
share of medium educated 0.500 0.036 0.512 0.023
share of high educated 0.231 0.041 0.212 0.042
population density 0.408 0.732 0.006 0.641
share with managed-care plan 0.174 0.037 0.169 0.055
share with supplementary insurance 0.554 0.037 0.568 0.043
share with high deductible 0.431 0.043 0.429 0.043
# observations 6162 4544
Notes: Based on the sample of physicians in German-speaking Switzerland for the period
2008-2010. All variables are measured annually on the physician level. Costs are in 2010
Swiss francs and measured in retail prices as charged at the doctor’s office.
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density. In addition, the local population in these regions are on average somewhat
healthier, less urbanized and have smaller shares of immigrants and unemployed.
The next section investigates these differences in covariates more closely.
5.3 Assessing Common Support
Since treatment effects (policy effects) can only be estimated for the common sup-
port, assessing the overlap of covariate distributions between treatment and control
groups is of great importance. A useful starting point is to inspect scale-free normal-
ized differences (instead of t-statistics), which indicate how difficult it is to adjust for
differences in covariates when estimating policy effects.13 Imbens and Wooldridge
(2009) state that, as a rule of thumb, normalized differences exceeding 0.25 in ab-
solute value should invoke caution when using simple regression methods. Table 2
shows that for some covariates, normalized differences clearly exceed one quarter in
absolute value such as for the number of patients, the physician density, and several
of the socio-economic variables. These findings suggest that appropriately adjust-
ing for differences in covariates might be difficult when estimating policy effects,
and moreover, attention must be paid to missing overlap in the covariate distribu-
tions. To proceed further, we estimate the propensity score with a logit model to
investigate the group-specific densities of the propensity score values, see Figure 1.
Figure 1: Kernel Densities of Estimated Propensity Scores
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(a) full sample
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(b) common support
As we can see from the high probability mass at the boundaries of the [0 , 1]
13The normalized difference of covariate j is computed as (x̄j1 − x̄j0)/
√
V̂j1 + V̂j0, where x̄jd
and V̂jd are the sample mean and the sample variance, respectively, estimated in the subsample
with Di = d ∈ {0, 1}. Imbens and Wooldridge (2009) argue that t-statistics are not useful in this
context because the problem of differences in covariates is invariant to sample size.
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Table 2: Normalized Differences of Covariates Means (2008-2010)
full c.s. full c.s.
sample sample sample sample
physician characteristics share of immigrants -0.108 -0.049
female -0.018 0.002 fraction of urban area -0.381 -0.266
German nationality 0.073 0.062 net income per capita in 1000 0.095 -0.025
other foreign nationality -0.046 -0.026 unemployment rate -0.309 -0.179
age -0.147 -0.103 share of medium educated 0.201 0.160
work experience -0.124 -0.089 share of high educated -0.269 -0.243
patient pool variables population density -0.340 -0.245
# patients -0.269 -0.243 share with special managed-care plan -0.078 0.014
# visits per patient 0.157 0.126 share with supplementary insurance 0.254 0.158
patients’ average age -0.172 -0.113 share with high deductible 0.029 0.002
cases aged > 80y -0.107 -0.042 speciality type
cases aged 66 − 80y -0.111 -0.070 gynecologist 0.006 -0.014
cases aged < 25y 0.171 0.128 angiologist -0.013 -0.021
cases by males -0.004 0.002 cardiologist -0.061 -0.032
characteristics of the local health care market invasive specialist 0.018 0.006
physician density -0.362 -0.261 other type of specialist 0.119 0.127
share with very good subj. health 0.276 0.201
share with good subj. health -0.070 -0.044 α̂ 0.099
share with very good obj. health 0.211 0.194 # control obs. (non-dispensing) 6162 5339
share with good obj. health 0.109 0.058 # treated obs. (dispensing) 4544 3889
share with chronic health problems -0.209 -0.130 # control individuals (non-dispensing) 2215 1908
share with high health risk -0.402 -0.334 # treated individuals (dispensing) 1658 1416
Notes : common support refers to the subsample of observations inside the interval [ α̂, 1 − α̂]. The normalized
difference of covariate j is computed as (x̄j1 − x̄j0)/
√
V̂j1 + V̂j0, where x̄jd and V̂jd are the sample mean and
the sample variance, respectively, estimated in the subsample with Di = d ∈ {0, 1}. Data Sources : Sasis AG,
MedReg, SHS, SFSO, SFFA.
interval in Figure 1 (a), there are a fair number of observations for which treatment
status is almost perfectly predicted. That is, these observations are in areas of the
covariate space where there are no units of the opposite group and therefore lie
outside the common support. To restrict the sample to the common support, we
follow the approach recently proposed by Crump et al. (2009). Compared to other
methods where researchers have to choose trimming parameters in an ad hoc fashion
(cf. Smith and Todd, 2005), this method has the advantage that it is purely data-
driven and straightforward to implement because it is solely based on the marginal
distribution of the propensity score. The aim is to compute the cut-off parameter
α that solves the minimization problem derived in Crump et al. (2009, p. 193) and
then to restrict the sample to those observations satisfying p̂(x) ∈ [α̂, 1 − α̂]. Using
their algorithm, we find α̂ = 0.099 and consequently about 14% of the sample are
dropped. Given the common-support sample, the propensity score model is then
re-estimated (cf. Crump et al., 2009). For detailed results of the propensity score
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estimation, the reader is referred to the Online-Appendix C.
The effect of this procedure is illustrated in two ways. First, the re-estimated
propensity score should no longer include values close to zero and one. Indeed,
Figure 1 (b) shows that the probability mass close to the boundaries is practically
reduced to zero such that the common support assumption now seems likely to be
satisfied. Second, the covariate distributions of the treatment and the control group
become more balanced as can be seen from normalized differences calculated in the
common-support sample in Table 2. Comparing values, we see that, as expected,
the magnitude of normalized differences becomes sizably smaller (and thus covariate
distributions more balanced) when moving from the full sample to the common-
support sample. Importantly, the largest values in the full sample (e.g. population
density, physician density, share of urban area, unemployment rate), drop markedly
by about 25 to 50 percent. Overall, this means that adjusting for differences in
covariates will be much less critical when estimating treatment effects.
5.4 Policy Effects of Dispensing
We now proceed to estimate the effect of the dispensing policy on the health care
expenditures triggered by physicians. As mentioned, we use expenditures per patient
as dependent variables to reduce the variation induced by differences in practice size.
Note further that we do not take logarithms because it changes the interpretation
of average policy effects in an undesired way.14 The set of covariates used in the
doubly robust regression methods is essentially the same as the one presented in
Table 2 plus year-specific intercepts, but without the number of patients (because
we consider per-patient outcomes). Due to the fairly large number of covariates, only
main effects are included in the specification.15 Standard errors are obtained by 1000
bootstrap iterations, taking into account the clusters of repeated observations across
years and the sampling bias resulting from the first-step estimation of the propensity
score. When assessing the two different specifications of the outcome model, we have
to rely on appropriate goodness-of-fit measures because the linear and exponential
models are non-nested. Applying the Bayesian Information Criterion (BIC), the
exponential model is found to fit the data better, which implies that the WPQML
14When outcomes are in logs, treatment effects measure the approximate percentage difference
in geometric means, and not in arithmetic means. From a policy perspective, the geometric-mean
interpretation is not meaningful at all.
15We also tested extended specifications including higher-order terms. While the qualitative
results did not change, estimates were found to be less precise.
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is preferable relative to the WLS.16 For detailed estimation results, the reader is
referred to Appendix C.
The main results are presented in Table 3. We start by discussing the effect
Table 3: Policy Effects of Dispensing, 2008 − 2010
Drug Costs per Patient Non-drug Costs per Patient
% of % of
Coef. S.E. mean Coef. S.E. mean
Unadjusted Difference 56.03** (23.03) 25.89% 88.54** (18.98) 21.24%
Average Treatment Effect (ATE)
WLS 138.83** (29.74) 64.15% 106.99** (13.73) 25.66%
WPQML 96.04** (21.67) 44.38% 105.62** (12.80) 25.34%
Average Treatment Effect on the Treated (ATT)
WLS 76.48** (25.69) 30.74% 98.82** (17.08) 21.11%
WPQML 71.87* (32.04) 28.88% 97.67** (16.78) 20.87%
Notes : The estimation sample consists of all physicians in the years 2008-2010 that lie in the
common support. Outcomes are measured annually on the physician level. The set of covariates
used is the one presented in Table 2 including year-specific intercepts. Standard errors are
bootstrapped and clustered at the physician level using 1000 replications. Significance levels:
** p<0.01 and * p<0.05. Data Sources : Sasis AG, MedReg, SHS, SFSO, SFFA.
of dispensing on physicians’ drug costs displayed on the left-hand side. First, the
estimated policy effects imply that dispensing raises a physician’s total annual drug
expenditure in per-patient terms by roughly CHF 75 (30%) in the population of dis-
pensing physicians (ATT). The estimates from WLS and WPQML are very similar
in terms of magnitude. In the overall physician population (ATE), effects are larger
and differ somewhat between estimators. (Note that the WPQML estimate is more
precise.) These results lend support to the notion that physicians prescribe larger
amounts or more expensive drugs when allowed to dispense. Next, it is interesting
to note that all estimated policy effects are larger than the observed difference in
means which corresponds to a negative selection effect (selection effect = unadjusted
difference − ATT). That is, if we were to estimate the policy effect naively by the
raw difference in means, we would underestimate the true effect of dispensing. Put
differently, the interpretation of the negative selection effect is that regions with
dispensing would have lower average costs in the absence of dispensing than regions
where dispensing is banned under the current regime. The normalized differences
(Table 2) suggest that health care market conditions are likely to be the most rele-
16The BIC is defined as ln( SSRN ) +
k ln(N)
N . For drugs per patient, for instance, estimation of
the outcome model in the two subsamples (Di = 0; Di = 1) produce BICs of (12.55; 12.41) in the
exponential specification and (12.61; 13.06) in the linear specification. Since the the former has
smaller values in both subsamples, the WPQML estimator is preferred to the WLS estimator.
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vant “drivers” of the selection effect. Furthermore, there is some discrepancy in the
relative magnitude of the ATE and the ATT which is an indication for treatment
effect heterogeneity among dispensing and non-dispensing physicians. On the whole,
the findings discussed so far suggest that physicians respond quite strongly to the
financial incentives created by the markup they earn when dispensing prescription
drugs. In this sense, our results are in line with Liu et al. (2009), Rischatsch et al.
(2009), and Iizuka (2007, 2012), who find that the prescription choices of dispensing
physicians are influenced by the markup (see Section 2).
Besides drug costs, we also examine whether dispensing affects non-drug medical
expenditure, as presented on the right-hand side of Table 3. We find that dispens-
ing also increases non-drug costs by around 20-25%. All estimates are significant
on the 1% level and very similar across the two estimators. These results point to a
complementary relationship between drug expenditure and other forms of medical
expenditure in the context of policy-induced health care expenditures. (In our ex-
tended analysis, we find that dispensing does not significantly affect the cost share
of drug expenditures, see the left-hand side of Table 4. This is the same as saying
that the relative effect on drug costs is not significantly different from the relative ef-
fect on non-drug costs.) There are two explanations for this complementarity. First
and more likely, prescribing additional medication is likely to increase the total time
of treatment. This may come about because physicians must spend additional time
entering the prescription information into the patient’s record, fetching the drug
from storage, informing the patient on recommended drug intake and potential side
effects, and adding the prescription to the patient’s invoice. This automatically
results in higher non-drug costs because consultation costs are increasing in consul-
tation time. Second, a dispensing physician may be tempted to perform additional
tests or examinations he would not otherwise perform in order to “justify” the dis-
pensing of additional prescription drugs to the patient. While this represents a
rather severe form of malpractice, we consider this second explanation to be less
likely than the first explanation.
To explore these issues somewhat further, we test whether the reported increase
in non-drug expenditure may be due to the possibility that dispensing physicians
induce more visits than non-dispensing physicians, ceteris paribus. The results on
the right-hand side in Table 4 suggest that the dispensing status does not signifi-
cantly affect the number of visits per patient. Thus, we can exclude the possibility
that the positive effect on non-drug expenditures is due to induced follow-up visits.
This implies that dispensing leads to more medical services per visit, which lends
support to the arguments presented above.
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Table 4: Policy Effects of Dispensing, 2008 − 2010
Share of Drug Costs Visits per Patient
% of % of
Coef. S.E. mean Coef. S.E. mean
Unadjusted Difference -0.020** (0.006) -9.25% -0.007 (0.059) -0.28%
Average Treatment Effect (ATE)
WLS 0.004 (0.006) 1.89% 0.050 (0.031) 1.95%
WPQML 0.001 (0.006) 0.63% 0.049 (0.030) 1.95%
Average Treatment Effect on the Treated (ATT)
WLS 0.005 (0.006) 2.63% 0.003 (0.067) 0.13%
WPQML 0.003 (0.006) 1.62% -0.003 (0.059) -0.14%
Notes : The estimation sample consists of all physicians in the years 2008-2010 that lie
in the common support. Outcomes are measured annually on the physician level. The
set of covariates used is the one presented in Table 2 including year-specific intercepts.
Standard errors are bootstrapped and clustered at the physician level using 1000 repli-
cations. Significance levels: ** p<0.01 and * p<0.05. Data Sources : Sasis AG, MedReg,
SHS, SFSO, SFFA.
6 Conclusions
When physicians can earn a markup on dispensing prescription medication, they
have financial incentives to over-prescribe or administer more expensive treatment
combinations. This paper has empirically tested whether the dispensing policy af-
fects outpatient health care costs. Using comprehensive insurance-claims data from
Switzerland, we estimate treatment effects (policy effects) by exploiting the fact
that there is regional variation in the dispensing policy. We employ estimation pro-
cedures that combine inverse probability weighting and regression, which are more
robust to misspecification than methods based on regression alone or the propensity
score alone.
Our benchmark estimates suggest that the dispensing permission increases drug
expenditures considerably. On top, dispensing is also found to raise non-drug medi-
cal costs, which points to a complementary relationship between drug and non-drug
costs in the context of policy-induced demand. These findings are of high relevance
for health care policy because they imply that outpatient health care expenditure
can be reduced considerably by completely separating the prescribing and dispensing
of prescription medication.
There are some limitations to our analysis. In particular, our dataset does not
include out-of-pocket expenditure where over-prescribing could also be relevant. Fur-
thermore, the data does not allow us to investigate as to how health outcomes are
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affected by dispensing. These issues could be tackled if more detailed data were
available. Nevertheless, our study presents clear evidence that the dispensing per-
mission affects the prescribing behavior of physicians in ways that have important
implications for health care policy.
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Appendix
A Drug Dispensing and Pricing in Switzerland
A.1 Physician Dispensing (2000 − 2010)
Switzerland consists of 26 cantons (states). As Table A.1 shows, 18 cantons have “pure”
policies, i.e. physician dispensing is either completely allowed or prohibited. However, four
cantons have policies that result in a de facto ban. For example, the canton of Aargau
applies a distance-to-pharmacy criterion, i.e. if the nearest pharmacy from the physician’s
office cannot be reached within one hour by public transport, the physician is allowed to
dispense. This regulation leads to an almost complete ban of physician dispensing.
In the four cantons with a mixed system, the dispensing rule is determined on the
municipal level. In the cantons Bern and Graubünden, physician dispensing is banned
in communities where the (emergency) supply and accessibility of drugs is sufficiently
guaranteed by pharmacies. Concretely, at least one pharmacy with all-day emergency
supply has to be available in municipalities of the canton of Graubünden and in the
canton of Bern at least two pharmacies are required. Otherwise, physicians are allowed to
dispense drugs without restrictions. As a result, physicians in these two cantons are mainly
allowed to dispense drugs in rural areas. Finally, physician dispensing is not allowed in
the two largest cities of the canton of Zürich (Zürich and Winterthur) and the canton of
Schaffhausen (Schaffhausen and Neuhausen), respectively, while it is allowed in all other
municipalities.17
Table A.1: Physician dispensing regulations (2008 − 2010)
Dispensing Cantons Total
allowed Appenzell Innerrhoden, Appenzell Ausserrhoden, Basel-
Landschaft, Glarus, Lucerne, Obwalden, Nidwalden, St.
Gallen, Solothurn, Schwyz, Thurgau, Uri, Zug
13
banned Aargau1, Basel-Stadt, Fribourg1, Geneva2, Jura1,2,
Neuchatel2, Ticino2, Vaud2, Valais1
9
mixed Bern, Graubünden, Schaffhausen, Zürich 4
Notes : (1) drug dispensing banned with exception, (2) only French- or Italian-
speaking
A.2 Drug Price Regulations
The retail prices of all drugs that are covered by the mandatory health insurance are
determined by government regulations. The retail price consists of the ex-factory price18
plus two additional distribution fees that are charged to cover the cost of the retailer, e.g.
17Recently, the cantons Zürich (ZH) and Schaffhausen (SH) changed the regulations. After a
ballot in the canton of Zürich in 2008, where 53.7% of the cantonal electorate voted for physician
dispensing, physicians in Zürich and Winterthur are allowed to dispense drugs as of May 2012.
Similarly, physician dispensing will be completely allowed in the canton of Schaffhausen after a
ballot in 2012 that concluded with 71.5% yes votes.
18The ex-factory price is set by the federal government and depends on prices of drugs with
the same drug action and on drug prices in other European countries with similar pharmaceutical
sectors (Austria, France, Germany, Denmark, the Netherlands and the United Kingdom).
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shipping or warehousing costs. Since the distribution fees increase with the ex-factory
price, the absolute markup for the physician (and the pharmacist) is increasing in the
ex-factory price (see Table A.2).
Table A.2: Additional distribution fees
ex-factory price (CHF) additional fee, additional fee (CHF), Retail price (CHF),
price dependent per package excl. VAT
0.05 - 4.99 12.0% 4.00 4.06 - 9.59
5.00 - 10.99 12.0% 8.00 13.60 - 20.31
11.00 - 14.99 12.0% 12.00 24.32 - 28.79
15.00 - 879.99 12.0% 16.00 32.80 - 1001.59
880.00 - 2569.99 7.0% 60.00 1001.60 - 2809.89
> 2570.00 0.0% 240.00 > 2810.00
The price of pharmaceuticals charged by dispensing physicians corresponds to the re-
tail price plus 2.5% VAT. However, the price charged by pharmacies is higher due to two
additional lump-sum fees. First, the pharmacist receives CHF 4.20 for checking the pre-
scription. This fee is charged only once per drug and prescription. Second, the pharmacist
maintains records about patients’ drug consumption and checks for potential adverse in-
teractions with other drugs. This fee (CHF 1.89) is charged each time the patient buys
at least one package. Given this particular price setting regime, the pharmacists earn an
excess markup compared to the physician.
B Variable Definitions and Construction
Table A.3: Variable Definitions and Construction
Variable Name Description/Construction Aggre-
gation
Source
direct drug costs a physician’s total real annual drug costs resulting from direct
dispensing. Inflation-adjusted to 2010 constant retail prices (Swiss
francs) by using the appropriate sub-indices from the Swiss CPI.
Sasis AG
indirect drug costs a physician’s total real annual drug costs resulting from issued
prescriptions that are filled in pharmacies. Inflation-adjusted to
2010 constant retail prices (Swiss francs) by using the appropri-
ate sub-indices from the Swiss CPI. Note: the excess markup
of pharmacies is adjusted for by the procedure explained in the
Online-Appendix C.
Sasis AG
drug costs direct + indirect drug costs Sasis AG
nondrug costs a physician’s total annual non-drug medical expendi-
ture. In constant 2010 Swiss francs. Canton-specific
price level differentials are adjusted for. Source:
http://www.praxishilfe.ch/seiten/tpw tarmed.html.
Sasis AG
cost share of drugs drug costs/non-drug costs Sasis AG
drug costs per patient drug costs/# patients Sasis AG
nondrug costs per patient non-drug costs/# patients Sasis AG
share of dispensed drugs direct drug costs/drug costs Sasis AG
Continued on next page
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Table A.3 – Continued from previous page
Variable Name Description/Construction Aggre-
gation
Source
dispensing status, Di =1, if physician is dispensing, =0 if physician is not dispens-
ing. For physicians where information is not available in MedReg
(15%), we define the dispensing status based on the policy rule
prevailing in their office location. Moreover, similar to the ap-
proach taken by Iizuka (2012), we attempt to reduce measure-
ment error in Di by re-defining a physician to be dispensing (non-
dispensing) if this share of dispensed drugs exceeds 75% (is below
25%). This results in effective changes of dispensing status for
roughly 3% of the sample.
MedReg,
Sasis AG
female =1 if physician is female, =0 if physician is male MedReg
German nationality =1 if physician has German nationality, =0 otherwise MedReg
other foreign nationality =1 if physician has foreign nationality other than German, =0
otherwise
MedReg
age current year - year of graduation from medical school + 26, where
26 is the average age at graduation
MedReg
work experience current year - year of attainment of specialty title MedReg
# patients the total number of patients who come to the physician’s office in
the calendar year
Sasis AG
# visits the total number of visits to the physician’s office in a calendar
year
Sasis AG
# visits per patient # visits/# patients Sasis AG
patients’ average age sum of patients’ age/# patients Sasis AG
cases aged > 80y # visits by patients aged above 80/# visits Sasis AG
cases aged 66 − 80y # visits by patients aged btw. 66-80/# visits Sasis AG
cases aged < 25y # visits by patients aged below 25/# visits Sasis AG
cases of males # visits by male patients/# visits Sasis AG
physician density The physician density is the total number of physicians per 1000
inhabitants in a municipality.
1 MedReg,
SFSO
share with very good subj.
health
the share of the population who self-report very good health in
the region.
2 SHS
share with good subj. health cf. previous 2 SHS
share with very good obj.
health
symptom-based measure. The share of the population in a region
who have very good objective health. Objective health is con-
structed by summing the following indicators: pain in the back,
adynamia, abdominal pain, looseness or costiveness, sleep disor-
der, headache, heart palpitation or ventricular extrasystole, pain
or pressure in the chest, joint pain or pain in the limbs, and pain
in the hands. Each variable can take the values 0 (=no symp-
toms), 1 (=light symptoms) or 2 (=strong symptoms). The sum
of these variables is recoded as follows: 0-1 (=very good health),
2-3 (=good health), 4-6 (=fair health) and >6 (=poor health).
2 SHS
share with good obj. health cf. previous 2 SHS
share with chronic health
problems
treatment-based measure. The share of the population in a region
that was under medical treatment due to at least one of the fol-
lowing chronic conditions: migraine, asthma, diabetes, arthrosis,
stomach ulcer, osteoporosis, chronic bronchitis, high blood pres-
sure, heart attack, apoplexy, renal disease, cancer, allergy, and
depression.
2 SHS
share with high health risk diagnosis-based measure. The share of the population in a region
diagnosed with high blood pressure, high cholesterol level, and/or
diabetes.
2 SHS
Continued on next page
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Table A.3 – Continued from previous page
Variable Name Description/Construction Aggre-
gation
Source
share of immigrants percentage of non-Swiss citizens in the permanent resident popu-
lation of a municipality
1 SFSO
fraction of urban area percentage of urbanized acreage relative to total acreage of a mu-
nicipality
1 SFSO
net income per capita in 1000 average net income per-capita (2008) in 1,000 Swiss francs in mu-
nicipality
1 SFFA, SFSO
unemployment rate percentage of unemployed in total workforce in municipality 1 SFSO
share of medium educated percentage of vocational and secondary school graduates relative
to total adult population in municipality
1 SFSO
share of high educated percentage of college and university graduates relative to total
adult population in municipality
1 SFSO
population density log of population in 1000 per square kilometre in municipality 1 SFSO
share with managed-care plan percentage of the population enrolled in managed-care insurance
plans (HMO and others) in region
2 SHS
share with supplementary in-
surance
percentage of the population with supplementary health care in-
surance in region
2 SHS
share with high deductible percentage of the population who choose a high deductible (>1000
Swiss francs) in region
2 SHS
non-invasive specialist reference group. =1 if specialty includes dermatology, venereol-
ogy, specialty for allergies and immunology, endocrinology, pneu-
mology, nephrology, neurology, hematology, gastroenterology, on-
cology, physical medicine and rehabilitation, specialty for infec-
tious diseases, tropical medicine, metabolic pathology and neu-
ropathology, =0 otherwise
Sasis AG
gynecologist =1 if gynecologist, =0 otherwise Sasis AG
angiologist =1 if angiologist, =0 otherwise Sasis AG
cardiologist =1 if cardiologist, =0 otherwise Sasis AG
invasive specialist =1 if specialty is surgery, pediatric surgery, ophthalmology, or-
thopaedy, vascular surgery, urology, jaw and facial surgery, plastic
surgery, or hand surgery, =0 otherwise
Sasis AG
other type of specialist =1 if specialty is anesthetics, radiology, industrial medicine,
pathology, pharmaceutical medicine, radio-oncology, intensive-
care specialty, nuclear medicine, clinical pharmacology and toxi-
cology, genetics, or other non-classified specialty, =0 otherwise
Sasis AG
Aggregation 1: For each physician i, we compute a weighted average across municipalities. The share of visits at
physician i’s office due to people living in these municipalities is used as a weight.
Aggregation 2: For each physician i, we compute a weighted average across regions. The share of visits at physician i’s
office due to people living in these regions is used as a weight. Note: the SFSO divides Switzerland into 106 so-called
mobility regions.
Data Sources: Sasis AG: nationwide operator of the insurance claims database of Swiss health insurers, MedReg:
federal register of medical professionals, SFSO: Swiss Federal Statistical Office, SHS: Swiss Health Survey, SFFA:
Swiss Federal Finance Administration
C Online Appendix
Supplementary information and tables to this paper can be found on the homepage
of the corresponding author: http://staff.vwi.unibe.ch/schmid/downloads/
pd_wp_appendix_jul13.pdf
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